Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ecabet · 2 trials · 2 indications
The Schirmer's test is used determine if tear glands produce enough tears to keep eyes adequately moist. Calibrated strips of a non-toxic filter paper are used. One free end is placed within the lower eyelid. At the conclusion of the test, the paper strip is removed from the lower eyelid and the amount of wetting of the paper strip is measured.
ocular signs, including corneal and conjunctival staining, tear film breakup time and blink rate, and ocular symptoms, including burning or stinging, itchiness or scratchiness, grittiness or sandiness, foreign body sensation, haziness or blurriness, photophobia, photopsia, and eye discomfort
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | ecabet ophthalmic solution |
| 2 | PLACEBO_COMPARATOR | Placebo comparator |
| Ecabet | EXPERIMENTAL | Ophthalmic solution in the Study eye four times daily for 90 days. |
| Placebo | PLACEBO_COMPARATOR | Ophthalmic solution in the Study eye four times daily for 90 days. |
| Name | Type | Description |
|---|---|---|
| ecabet ophthalmic solution | DRUG | sterile ophthalmic solution |
| placebo | DRUG | sterile ophthalmic solution |
| Ecabet | DRUG | ophthalmic solution 2.83% |
Inclusion Criteria: * Diagnosed with dry eye disease Exclusion Criteria: * Dry eye disease secondary to surgery
Top 20 of 34 competitors
Ecabet is an investigational small molecule being developed for the treatment of dry eye disease and dry eye syndromes. It is formulated as an ophthalmic solution and is currently in clinical development for these ophthalmology indications.
Ecabet is being developed by Bausch + Lomb Corporation, a company traded on the New York Stock Exchange under the ticker symbol BLCO. The company is conducting clinical trials to evaluate the safety and efficacy of Ecabet ophthalmic solution.
Ecabet is in Phase 2 clinical development. Two Phase 2 trials have been completed for the treatment of dry eye disease and dry eye syndromes. The drug is investigational and has not yet been approved by regulatory authorities.
Ecabet has been studied in two completed Phase 2 clinical trials. NCT00370747 evaluated Ecabet ophthalmic solution for treating dry eye syndrome with 162 participants, and NCT00667004 evaluated Ecabet in dry eye disease with 183 participants. Both trials were conducted in the United States.
Ecabet is also known by its chemical name ecabet sodium. In clinical trials, it is referred to as Ecabet ophthalmic solution. No other alternative names have been associated with this drug in the available clinical trial information.